Therapeutic Solutions International,
Inc., Announces the Appointment
of
Nassir Azimi, MD, to Science
Board
Company to Initiate
Investigational Cardiovascular Study with Dr. Azimi
and NanoStilbene
Oceanside, CA
-- May
9, 2018
--
InvestorsHub NewsWire -- Therapeutics
Solutions International, Inc., (OTC
Markets:
TSOI) announced today
that Nassir
Azimi, M.D.,
has been
appointed to the Company's
Scientific Advisory
Board. In addition to
this, Dr. Azimi
plans to
work with the Company to investigate the use
of its
product
NanoStilbene
in heart attack
victims.
Dr.
Azimi attended Dartmouth Medical School and completed his residency
at the University of Colorado. He finished his four-year fellowship
in Cardiovascular and Peripheral Interventions at Yale University
in New Haven. Dr. Azimi has been in
private practice for over 13
years
establishing
a
thriving
clinical practice for cardiac patients as well as treating patients
for peripheral vascular disease. He is active in Interventional
Cardiology and Peripheral Interventions. Dr. Azimi is the director
of La Mesa Cardiac Center's Nuclear Cardiology Laboratory. He is
also an investigator in multiple clinical research studies for
various cardiac and peripheral diseases.
Cardiovascular
disease and cancer are the largest contributors to the burden of
chronic disease in the United States. With an estimated 15 million
Americans with heart disease and 14 million with a history of
cancer, these numbers will undoubtedly rise as the population grows
older and therapies enhance longevity.
"Our Scientific Team
at TSOI proudly welcomes Dr. Azimi in joining us today and we are
very excited about the expertise he brings to our work.
Inflammation is a
unifying theme among a variety of diseases, including both
cardiovascular disease and cancer. Accumulating evidence
suggests that oxidative stress and its direct consequences,
including lipid peroxidation, are involved in numerous pathological
states including atherosclerosis, cancer, and
inflammation" said Timothy Dixon,
President, and CEO. "Dr. Azimi is a big
proponent on the uses of antioxidants such as our nanoparticle
pterostilbene product NanoStilbene, in cardiovascular
patients, a product included in two of our cancer vaccines in use
at the Pan Am Cancer Treatment Center in
Tijuana, Mexico we recently announced".
"I envision a world
where NanoStilbene is an essential adjunct to standard medical
treatment in patients with cancer and heart disease.
Cardiovascular
disease is
a leading
cause of death
in the
United States as well as worldwide.
With
improvements and developments of new novel therapies
for patients with cardiovascular disease remains
a primary
research
goal of
many clinicians and researchers. Apoptosis, necrosis, and
autophagy occur in
cardiac myocytes (the
muscle cells (myocytes) that make up the cardiac muscle (heart
muscle), and
both gradual and acute cell death are hallmarks of cardiac
pathology, including heart failure, myocardial
infarction,
and ischemia/reperfusion,"
said Dr. Azimi.
"By
supplementing NanoStilbene in heart attack patients we hope to show
a reduction in apoptosis of cardiomyocytes,"
added Dr.
Azimi.
"It is my honor to
work together with Dr. Azimi, a seasoned veteran in the area of
cardiovascular therapeutics, in developing interventions that
address the current unmet medical need of post-infarct cardiac
repair," said Dr.
Hong
Ma, the Company's Chief
Scientific Officer. "Given the excellent
track record of the pterostilbene molecule in modulating numerous
inflammatory and regenerative processes, we are enthusiastic to
rapidly translate animal studies into the clinical
arena."
About Therapeutic Solutions International,
Inc.
Therapeutic Solutions
International is focused on immune modulation for the treatment of
several specific diseases. Immune modulation refers to the ability
to upregulate (make more active) or downregulate (make less active)
one's immune system. The Company's corporate website is
www.therapeuticsolutionsint.com.
Safe
Harbor Statement
This
release contains forward-looking statements that are based upon
current expectations or beliefs, as well as a number of assumptions
about future events. Although we believe that the expectations
reflected in the forward-looking statements and the assumptions
upon which they are based are reasonable, we can give no assurance
that such expectations and assumptions will prove to have been
correct. Forward-looking statements are generally identifiable by
the use of words like "may," "will," "should," "could," "expect,"
"anticipate," "estimate," "believe," "intend," or "project" or the
negative of these words or other variations on these words or
comparable terminology. The reader is cautioned not to put undue
reliance on these forward-looking statements, as these statements
are subject to numerous risk factors as set forth in our SEC
filings. To the extent that statements in this press release are
not strictly historical, including statements as to product launch
timing, revenue projections, business strategy, outlook,
objectives, future milestones, plans, intentions, goals, future
collaboration agreements, or otherwise as to future events, such
statements are forward-looking, and are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. The forward-looking statements contained in this release
are subject to certain risks and uncertainties that could cause
actual results to differ materially from the statements
made.
CONTACT INFORMATION